Larger, longer trials would be needed for that
The failure to intensify therapy when treatment targets are not met is termed therapeutic inertia, which is a widely reported phenomenon that is known to negatively affect clinical outcomes, often through contributing to complications emanating from lack of glycemic control [15,16,17,18]
Similar content being viewed by others Introduction The presence of the blood-brain barrier (BBB), a tightly interconnected network of blood vessels and endothelial cells that restricts the entry of foreign particles larger than 100 nm into the brain, poses considerable challenges and complexities in advancing therapeutic strategies for neurodegenerative diseases (NDs) 1
As is shown in Figure 2, the average per cent change in the anagen to telogen hair ratio was in group 1 (supplement) +55.1%, in group 2 (lotion) +39.4%, and in group 3 (supplement and lotion) +63.5%, whereas in group 4 (no-treatment control) the average per cent change in the A/T ratio decreased by 3.9%
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
